Drugs / Netupitant/Palonosetron
Netupitant/Palonosetron
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04201769 Background | Nov 2016 → Apr 2020 | chemotherapy-induced toxicity | Consorzio Oncotech | Unknown | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Netupitant/Palonosetron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04201769 ↗ |
| Known as | NEPA | “all eligible patients will receive oral NEPA (300 mg netupitant/0.5 mg palonosetron), 60 minutes before chemotherapy” NCT04201769 ↗ |
| Known as | Netupitant/Palonosetron 300-0.5 milligrams Oral Capsule [AKYNZEO] | “Netupitant/Palonosetron 300-0.5 milligrams Oral Capsule [AKYNZEO]” NCT04201769 ↗ |
| Route | Oral | “all eligible patients will receive oral NEPA (300 mg netupitant/0.5 mg palonosetron), 60 minutes before chemotherapy” NCT04201769 ↗ |